phospho-NIPA(Ser354)抗体特异性结合抗原：抗体本身不能直接溶解或杀伤带有特异抗原的靶细胞，通常需要补体或吞噬细胞等共同发挥效应以**病原微生物或导致病理损伤。然而，抗体可通过与病毒或**的特异性结合，直接发挥中和病毒的作用。
产品编号xy- 8364R
英文名称phospho-NIPA(Ser354)
中文名称磷酸化间变性**瘤激酶核相互作用伴侣蛋白抗体
别 名NIPA (phospho S354); NIPA (phospho Ser354); p-NIPA (S354); p-NIPA (Ser354); hNIPA; Nuclear interacting partner of ALK; Nuclear interacting partner of anaplastic lymphoma kinase; ZC3HC1; Zinc finger C3HC type containing 1; NIPA_HUMAN.
说 明 书100ul
产品类型磷酸化抗体
研究领域肿瘤 细胞生物 **学 染色质和核信号 信号转导 激酶和磷酸酶
抗体来源Rabbit
克隆类型Polyclonal
phospho-NIPA(Ser354)抗体交叉反应 Human, Mouse, Rat, Dog, Pig, Horse, Rabbit,
产品应用WB=1:500-2000 ELISA=1:500-1000 IHC-P=1:400-800 IHC-F=1:400-800 ICC=1:100-500 IF=1:50-200 （石蜡切片需做抗原修复）
not yet tested in other applications.
optimal dilutions/concentrations should be determined by the end user.
分 子 量55kDa
细胞定位细胞核
性 状Lyophilized or Liquid
浓 度1mg/1ml
免 疫 原KLH conjugated synthesised phosphopeptide derived from human NIPA around the phosphorylation site of Ser354:TR(p-S)WD
亚 型IgG
纯化方法affinity purified by Protein A
储 存 液0.01M TBS(pH7.4) with 1% BSA, 0.03% Proclin300 and 50% Glycerol.
phospho-NIPA(Ser354)抗体保存条件Store at -20 °C for one year. Avoid repeated freeze/thaw cycles. The lyophilized antibody is stable at room temperature for at least one month and for greater than a year when kept at -20°C. When reconstituted in sterile pH 7.4 0.01M PBS or diluent of antibody the antibody is stable for at least two weeks at 2-4 °C.
PubMedPubMed
产品介绍background:
The regulated oscillation of protein expression is an essential mechanism of cell cycle control. The SCF class of E3 ubiquitin ligases is involved in this process by targeting cell cycle regulatory proteins for degradation by the proteasome, with the F-box subunit of the SCF specifically recruiting a given substrate to the SCF core. NIPA (nuclear interaction partner of ALK) is a human F-box-containing protein that defines an SCF-type E3 ligase (SCFNIPA) controlling mitotic entry. Assembly of this SCF complex is regulated by cell-cycle-dependent phosphorylation of NIPA, which restricts substrate ubiquitination activity to interphase. Nuclear cyclin B1 is a substrate of SCFNIPA. Inactivation of NIPA by RNAi results in nuclear accumulation of cyclin B1 in interphase, activation of cyclin B1-Cdk1 kinase activity, and premature mitotic entry. Thus, SCFNIPA-based ubiquitination may regulate S-phase completion and mitotic entry in the mammalian cell cycle.
Function:
Essential component of an SCF-type E3 ligase complex, SCF(NIPA), a complex that controls mitotic entry by mediating ubiquitination and subsequent degradation of cyclin B1 (CCNB1). Its cell-cycle-dependent phosphorylation regulates the assembly of the SCF(NIPA) complex, restricting CCNB1 ubiquitination activity to interphase. Its inactivation results in nuclear accumulation of CCNB1 in interphase and premature mitotic entry. May have an antiapoptotic role in NPM-ALK-mediated signaling events.
Subunit:
Interacts with the NPM-ALK fusion protein in a tyrosine phosphorylation-dependent manner. Interacts with SKP1. Component of a SCF(NIPA) E3 complex with SKP1, RBX1 and CUL1 when not phosphorylated on Ser-354. Interacts with CCNB1.
Subcellular Location:
Nuclear.
Tissue Specificity:
Widely expressed. Highly expressed in heart, skeletal muscle and testis. Expressed in brain, placenta, lung, kidney, liver, pancreas, spleen, thymus, prostate, ovary small intestine and colon. Weakly or not expressed in leukocytes.
Post-translational modifications:
hosphorylated. Phosphorylated on Ser residues at G2/M phase, but not during S and G0 phases. May also be weakly phosphorylated on Tyr residues. Ser-354 phosphorylation, a major site during the course of cell-cycle-dedendent phosphorylation, results in its dissociation from the SCF(NIPA) complex, thereby preventing CCNB1 degradation leading to mitotic entry.
Similarity:
Contains 1 C3HC-type zinc finger.
Gene ID:
51530
phospho-NIPA(Ser354)抗体（antibody,
Ab）是由效应B细胞（效应**B细胞）分泌，机体用于抵御外来物质，如病毒，**等抗原，结构呈“Y”字型的球状蛋白质，仅仅存在于脊椎动物的血液和B**细胞膜表面。凡是能够跟抗体结合的物质，均被称作抗原，因此对于抗抗体（能够结合抗体的抗体）来说，抗体本身也是一种抗原物质。
phospho-NIPA(Ser354)抗体普通抗体重链和轻链的结构
重链结构：普通的**球蛋白具有2条重链（H链），分子量约为50kD,有μ、δ、γ、ε和α五种重链亚型，对应的**球蛋白名称分别为IgM、IgG、IgA、IgD和IgE。
轻链结构： 普通**球蛋白具有2条轻链（L链），分子质量约25kDa，有κ链和λ链两种亚型，这两种轻链决定了Ig的亚型类别（IgG1，IgG2，IgG3，IgG4）。一个天然的Ig分子两条轻链总是相同的，但在同一个体内可存在分别带有κ或λ链的抗体分子。不同种属生物体内两型轻链的比例不同，正常人血清**球蛋白κ链：λ链约为2：1，而在小鼠的比例为20：1。
2.2抗体Fab段和Fc段
IgG经木瓜蛋白酶酶切后裂解为2个完全相同的Fab段和1个Fc段,每个Fab段都为单价,可与抗原结合但不会再发生凝集反应；经胃蛋白酶酶切后裂解为1个完整F(ab)2片段和碎片化的Fc片段,F(ab’)2片段为双价,可同时结合两个抗原表位。Fab段为抗原结合片段（fragment of antigen binding，Fab），相当于抗体分子的两个臂，由一个完整的轻链和重链的VH和CH1结构域组成。Fc段为可结晶段（fragment crystallizable，Fc）相当于Ig的CH2和CH3结构域，是Ig与效应分子或者细胞相互作用的部位。Fab段包含完整的可变区，以及恒定区的CH1区域。Fc段仅指Ig恒定区CH2和CH3的区域，相当于Y字结构下面那一部分。
合格 合格 LC3C 微管相关蛋白轻链3C抗体
合格 NRG3 神经调节蛋白3抗体
合格 IMPAD1 肌醇单磷酸酶IMPA3抗体
合格 合格 CAMKK2 钙调蛋白激酶激酶β抗体
合格 JIP1/MAPK8IP1 丝裂原活化蛋白激酶8相互作用蛋白1抗体
合格 合格 PTK6 酪氨酸蛋白激酶6/乳腺肿瘤激酶抗体
合格 Ret RET原癌基因抗体
合格 AKR1B10 醛糖还原酶相关蛋白质抗体
合格 ENPP2 核苷酸焦磷酸酶2抗体
合格 FUT8 岩藻糖转移酶8抗体
合格 Hepsin/TMPRSS1 跨膜蛋白酶丝氨酸1抗体
合格 合格 Bone Alkaline Phosphatase 骨碱性磷酸酶抗体
合格 Prostatic Acid Phosphatase 前列腺酸性磷酸酶抗体
合格 OVCA2 卵巢癌相关基因2蛋白抗体
合格 DRES17 乳腺癌相关蛋白DRES17抗体
合格 IFNA4 干扰素α4抗体
合格 GCMA 绒毛膜特异性转录因子GCMa抗体
合格 IL-6 白介素6抗体
合格 4 Hydroxynonenal 4羟基壬烯酸抗体
合格 Prostaglandin E Receptor EP1 前列腺素EP1受体抗体
合格 Acid sphingomyelinase 酸性神经鞘磷脂酶抗体
合格 IL-1 Beta 白介素1β抗体
合格 Annexin A8 膜粘连蛋白8抗体
合格 ICAM1 细胞间粘附分子1抗体